Press release |

Creative approach allows MSF to treat children with AIDS. But enormous challenges remain.

Geneva/Rio de Janeiro, 27 July 2005 — Médecins Sans Frontières is successfully treating an increasing number of children who have HIV/AIDS, according to data from MSF treatment programmes presented at a “late breaker” session at the 3rd International AIDS Society conference in Rio de Janeiro. MSF’s clinical outcomes are good despite the fact that currently available diagnostic tests and medicines are ill-adapted for children.

“We are committed to treating more children, even if no easy-to-use medicines designed for this purpose exist yet and we have to improvise solutions,” said Dr Pierre Humblet, coordinator of MSF’s international AIDS team. “Although clinical results presented in Rio are encouraging, in order to massively increase access to treatment for children, new or improved diagnostic and monitoring tests and treatments adapted for children are urgently needed.”

MSF presented data from a cohort of 1,840 children under 13 from Africa, Asia and Latin America . The observational study was conducted in 22 MSF programmes in 11 countries. All patients received antiretroviral treatment regimens recommended by the World Health Organization (WHO). In order to reach a larger number of children, MSF teams started treatment based on clinical or immunological criteria defined by WHO.

As of March 2005, 83.9% of the children were alive and on treatment. The probability of survival after six months was 94% and still as high as 91% after 24 months.

The health of the children in this study improved overall: they gained an average of 4 kg after 18 months. Only 5.5% of the patients experienced side-effects, and even fewer needed alternative treatment. Their immune systems recovered well: 73% of the children had a CD 4 count of more than 15% at 12 months.

Although these results are very encouraging, there are still huge gaps in diagnostic tools and children’s drug formulations which prevent the generalised scale-up of treatment for children. The World Health Organization (WHO) estimates that about 15% of the total amount of those on AIDS treatment should be children. There are 2.2 million children infected with HIV in the world. But only a fraction of the children with HIV/AIDS in need of treatment is receiving life-prolonging antiretroviral treatment today. As a result, half of all children with AIDS die before their second birthday. This is a problem for MSF as well, as only about 6% of the over 40,000 patients receiving antiretroviral treatment through MSF worldwide are children.

“HIV tests currently available in developing countries don’t work in infants under 18 months - this means that cases are missed and children die needlessly,” said Dr Felipe Garcia de la Vega, paediatrician and AIDS specialist with MSF’s Campaign for Access to Essential Medicines.

More resources to develop new tests are needed. To help remove obstacles in caring for children with HIV/AIDS, MSF intends to accelerate the development of new diagnostic tests by supporting promising projects that have so far lacked adequate backing and partners. The organisation will both try to define the specific needs for and uses of such tests and help to validate new tests.

Efforts to treat children with HIV/AIDS are further hampered by lack of appropriate drug formulations. Infants are given foul-tasting syrups or powders requiring clean water, yet it is difficult to measure liquids accurately. There are no paediatric fixed-dose combinations and in some MSF projects older children able to take tablets rely on split adult FDC tablets.

“We are obliged to find creative solutions when administering treatment to children,” said Dr Felipe Garcia de la Vega. Doctors and caregivers crush adult tablets, or break them in half, to achieve a suitable dosage for a child because fixed-dose combinations for children are not available. This practical challenge is compounded by the lack of clear guidelines including dosage charts for treating children with HIV.

“Despite the challenges, more children must be given antiretroviral treatment that extends and improves their lives,” said Dr Garcia de la Vega. “It may be difficult, but it is a responsibility we and other medical professionals cannot avoid.” MSF challenges the medical profession, scientists, governments and international organisations to step up all efforts to improve the care for children with AIDS.